Letter

Government regulation is needed to prevent biased under-reporting of clinical trials

BMJ 2004; 329 doi: 10.1136/bmj.329.7463.462-a (Published 19 August 2004)
Cite this as: BMJ 2004;329:462.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Iain Chalmers, editor, James Lind Library (ichalmers@jameslindlibrary.org)
  1. James Lind Initiative, Oxford OX2 7LG

    EDITOR—In 1996, Schering Healthcare published details of its ongoing randomised clinical trials in the Cochrane Library. The chief executive told me that he was doing this because industry's failure to disclose the results of its phase 3 trials could not be defended ethically or scientifically. Two years later, …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular